Maximizing bactericidal activity with combinations of bioreduced drugs

Future Medicinal Chemistry

Volumn 2, Issue 8, 2010, Pages 1253-1271

  Goldman, Robert C ^a  

^a RCG Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 4 [3 (2 NITRO 1 IMIDAZOLYL) PROPYLAMINO] 7 CHLOROQUINOLINE HYDROCHLORIDE; 4 [4 (2 NITRO 1 IMIDAZOLYL) BUTYLAMINO] 7 CHLOROQUINOLINE HYDROCHLORIDE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; CGI 17341; CGP 70520; FREE RADICAL; LL 3858; METRONIDAZOLE; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NICLOSAMIDE; NITAZOXANIDE; NITROFURAN DERIVATIVE; OLAQUINDOX; PA 647; QUINOXALINE DERIVATIVE; QUINOXALINE DI N OXIDE; TIRAPAZAMINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

BACTERICIDAL ACTIVITY; DRUG STRUCTURE; ENZYME KINETICS; HIGH THROUGHPUT SCREENING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG DISCOVERY; FREE RADICALS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NITROFURANS; NITROIMIDAZOLES; OXIDATION-REDUCTION; QUINOXALINES; TUBERCULOSIS;

EID: 77956052305     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.215     Document Type: Review

References (113)

1. Goldman RC, Plumley KV, Laughon BE. The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect. Disord. Drug Targets 7(2), 73-91 (2007).
2. Stover CK, Warrener P, Vandevanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405(6789), 962-966 (2000).
3. Choi KP, Bair TB, Bae YM, Daniels L. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG. J. Bacteriol. 183(24), 7058-7066 (2001).
4. Choi KP, Kendrick N, Daniels L. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J. Bacteriol. 184(9), 2420-2428 (2002).
5. Manjunatha UH, Boshoff H, Dowd CS et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103(2), 431-436 (2006).
6. Manjunatha UH, Lahiri R, Randhawa B, Dowd CS, Krahenbuhl JL, Barry CE 3rd. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob. Agents Chemother. 50(10), 3350-3354 (2006).
7. Singh R, Manjunatha U, Boshoff HI et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322(5906), 1392-1395 (2008).
8. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3(11), e466 (2006).
9. Li X, Manjunatha UH, Goodwin MB et al. Synthesis and anti-tubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)- (4-(trifluoromethoxy) benzyloxy)-6,7- dihydro-5H- imidazo[2,1-b][1,3] oxazines, analogues of PA-824. Bioorg. Med. Chem. Lett. 18(7), 2256-2262 (2008).
10. Kim P, Kang S, Boshoff HI et al. Structure-activity relationships of anti-tubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure- activity relationships. J. Med. Chem. 52(5), 1329-1344 (2009).
11. Kim P, Zhang L, Manjunatha UH et al. Structure-activity relationships of anti-tubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J. Med. Chem. 52(5), 1317-1328 (2009).
12. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun. Integr. Biol. 2(3), 215-218 (2009).
13. Anderson RF, Shinde SS, Maroz A, Boyd M, Palmer BD, Denny WA. Intermediates in the reduction of the anti-tuberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5H-imidazo[2, 1-b] [1,3]oxazine, in aqueous solution. Org. Biomol. Chem. 6(11), 1973-1980 (2008).
14. Maroz A, Shinde SS, Franzblau SG et al. Release of nitrite from the anti-tubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent. Org. Biomol. Chem. 8(2), 413-418 (2010).
15. Palmer BD, Thompson AM, Sutherland HS et al. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl] oxy}-6,7-dihydro-5H-imidazo[2, 1-b][1,3] oxazine (PA-824). J. Med. Chem. 53(1), 282-294 (2010).
16. Sutherland HS, Blaser A, Kmentova I et al. Synthesis and structure-activity relationships of anti-tubercular 2-nitroimidazooxazines bearing heterocyclic side chains. J. Med . Chem. 53(2), 855-866 (2010).
17. Thompson AM, Blaser A, Anderson RF et al. Synthesis, reduction potentials, and anti-tubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4- (trifluoromethoxy)benzyl]oxy}-6,7-dihydro- 5H-imidazo[2, 1-b][1,3]oxazine (PA-824). J. Med. Chem. 52(3), 637-645 (2009).
18. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52(10), 3664-3668 (2008).
19. Nuermberger E, Tyagi S, Tasneen R et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52(4), 1522-1524 (2008).
20. Nuermberger E, Rosenthal I, Tyagi S et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50(8), 2621-2625 (2006).
21. Tyagi S, Nuermberger E, Yoshimatsu T et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49(6), 2289-2293 (2005).
22. Papadopoulou MV, Bloomer WD, Mcneil MR. NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 29(6), 724-727 (2007).
23. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin. Cancer Res. 9(15), 5714-5720 (2003).
24. Tangallapally RP, Yendapally R, Lee RE et al. Synthesis and evaluation of nitrofuranylamides as novel anti-tuberculosis agents. J. Med. Chem. 47(21), 5276-5283 (2004).
25. Tangallapally RP, Yendapally R, Lee RE, Lenaerts AJ. Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents. J. Med. Chem. 48(26), 8261-8269 (2005).
26. Tangallapally RP, Lee RE, Lenaerts AJ. Synthesis of new and potent analogues of anti-tuberculosis agent 5-nitro-furan-2-carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability. Bioorg. Med. Chem. Lett. 16(10), 2584-2589 (2006).
27. Tangallapally RP, Yendapally R, Daniels AJ, Lee RE. Nitrofurans as novel anti-tuberculosis agents: identification, development and evaluation. Curr. Top. Med. Chem. 7(5), 509-526 (2007).
28. Budha NR, Mehrotra N, Tangallapally R et al. Pharmacokinetically guided lead optimization of nitrofuranylamide anti-tuberculosis agents. AAPS J. 10(1), 157-165 (2008).
29. Hevener KE, Ball DM, Buolamwini JK, Lee RE. Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorg. Med. Chem. 16(17), 8042-8053 (2008).
30. Hurdle JG, Lee RB, Budha NR et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J. Antimicrob. Chemother. 62(5), 1037-1045 (2008).
31. Rakesh, Sun D, Lee RB, Tangallapally RP, Lee RE. Synthesis, optimization and structure-activity relationships of 3,5-disubstituted isoxazolines as new anti-tuberculosis agents. Eur. J. Med. Chem. 44(2), 460-472 (2009).
32. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51(4), 1380-1385 (2007).
33. Maddry JA, Ananthan S, Goldman RC et al. Anti-tuberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb). 89(5), 354-363 (2009).
34. Ananthan S, Faaleolea ER, Goldman RC et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb.) 89(5), 334-353 (2009).
35. Khan A, Sarkar S, Sarkar D. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages. Int. J. Antimicrob. Agents 32(1), 40-45 (2008).
36. Walczak K, Gondela A, Suwinski J. Synthesis and anti-tuberculosis activity of N-aryl-C-nitroazoles. Eur. J. Med. Chem. 39(10), 849-853 (2004).
37. Sriram D, Yogeeswari P, Senthilkumar P, Sangaraju D. 5- nitrothiazolylthio-semicarbazones: synthesis and antimycobacterial evaluation against tubercular and non-tubercular mycobacterial species. J. Enzyme Inhib. Med. Chem. 25(1), 105-110 (2010).
38. Sriram D, Yogeeswari P, Dhakla P, Senthilkumar P, Banerjee D, Manjashetty TH. 5-nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species. Bioorg. Med. Chem. Lett. 19(4), 1152-1154 (2009).
39. Senthilkumar P, Dinakaran M, Yogeeswari P, Sriram D, China A, Nagaraja V. Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3- carboxylic acids. Eur. J. Med. Chem. 44(1), 345-358 (2009).
40. De Carvalho LP, Lin G, Jiang X, Nathan C. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J. Med. Chem. 52(19), 5789-5792 (2009).
41. Sisson G, Goodwin A, Raudonikiene A et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. 46(7), 2116-2123 (2002).
42. Hoffman PS, Sisson G, Croxen MA et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother. 51(3), 868-876 (2007).
43. Elazar M, Liu M, Mckenna SA et al. The antihepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2a via protein kinase activated by double-stranded RNA activation. Gastroenterology 137(5), 1827-1835 (2009).
44. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 284(43), 29798-29808 (2009).
45. Abreu FC, Goulart MO, Brett AM. Detection of the damage caused to DNA by niclosamide using an electrochemical DNA-biosensor. Biosens. Bioelectron. 17(11-12), 913-919 (2002).
46. Vicente E, Villar R, Burguete A et al. Efficacy of quinoxaline-2- carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. Antimicrob. Agents Chemother. 52(9), 3321-3326 (2008).
47. Villar R, Vicente E, Solano B et al. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J. Antimicrob. Chemother. 62(3), 547-554 (2008).
48. Vidakovic M, Crossnoe CR, Neidre C, Kim K, Krause KL, Germanas JP. Reactivity of reduced [2Fe-2S] ferredoxins parallels host susceptibility to nitroimidazoles. Antimicrob. Agents Chemother. 47(1), 308 (2003).
49. Crossnoe CR, Germanas JP, Lemagueres P, Mustata G, Krause KL. The crystal structure of Trichomonas vaginalis ferredoxin provides insight into metronidazole activation. J. Mol. Biol. 318(2), 503-518 (2002).
50. Valdez CA, Tripp JC, Miyamoto Y et al. Synthesis and electrochemistry of 2-ethenyl and 2-ethanyl derivatives of 5-nitroimidazole and antimicrobial activity against Giardia lamblia. J. Med. Chem. 52(13), 4038-4053 (2009).
51. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am. J. Gastroenterol. 104(12), 3069-3079 (2009).
52. Kaakoush NO, Asencio C, Megraud F, Mendz GL. A redox basis for metronidazole resistance in Helicobacter pylori. Antimicrob. Agents. Chemother. 53(5), 1884-1891 (2009).
53. Kim SY, Joo YM, Lee HS et al. Genetic analysis of Helicobacter pylori clinical isolates suggests resistance to metronidazole can occur without the loss of functional rdxA. J. Antibiot. (Tokyo) 62(1), 43-50 (2009).
54. Sisson G, Jeong JY, Goodwin A et al. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene. J. Bacteriol. 182(18), 5091-5096 (2000).
55. Olekhnovich IN, Goodwin A, Hoffman PS. Characterization of the NAD(P)H oxidase and metronidazole reductase activities of the RdxA nitroreductase of Helicobacter pylori. FEBS J. 276(12), 3354-3364 (2009).
56. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev. 14(1), 150-164 (2001).
57. Pal D, Banerjee S, Cui J, Schwartz A, Ghosh SK, Samuelson J. Giardia, Entamoeba and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob. Agents Chemother. 53(2), 458-464 (2009).
58. Lofmark S, Fang H, Hedberg M, Edlund C. Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob. Agents Chemother. 49(3), 1253-1256 (2005).
59. Pumbwe L, Chang A, Smith RL, Wexler HM. BmeRABC5 is a multidrug efflux system that can confer metronidazole resistance in Bacteroides fragilis. Microb. Drug Resist. 13(2), 96-101 (2007).
60. Vicente E, Perez-Silanes S, Lima LM et al. Selective activity against Mycobacterium tuberculosis of new quinoxaline 1,4-di-N-oxides. Bioorg. Med. Chem. 17(1), 385-389 (2009).
61. Vicente E, Duchowicz PR, Castro EA, Monge A. QSAR analysis for quinoxaline-2- carboxylate 1,4-di-N-oxides as anti-mycobacterial agents. J. Mol. Graph. Model. 28(1), 28-36 (2009).
62. Romeiro NC, Aguirre G, Hernandez P et al. Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg. Med. Chem. 17(2), 641-652 (2009).
63. Vicente E, Charnaud S, Bongard E et al. Synthesis and antiplasmodial activity of 3-furyl and 3-thienylquinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Molecules 13(1), 69-77 (2008).
64. Urquiola C, Gambino D, Cabrera M et al. New copper-based complexes with quinoxaline N1,N4-dioxide derivatives, potential antitumoral agents. J. Inorg. Biochem. 102(1), 119-126 (2008).
65. Marin A, Moreira Lima L, Solano B et al. Antiplasmodial structure-activity relationship of 3-trifluoromethyl-2-arylcarbonylquinoxaline 1,4-di-N-oxide derivatives. Exp. Parasitol. 118(1), 25-31 (2008).
66. Solano B, Junnotula V, Marin A et al. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues. J. Med. Chem. 50(22), 5485-5492 (2007).
67. Urquiola C, Vieites M, Aguirre G et al. Improving anti-trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives by complexation with vanadium. Bioorg. Med. Chem. 14(16), 5503-5509 (2006).
68. Zarranz B, Jaso A, Aldana I et al. Synthesis and antimalarial activity of new 3-arylquinoxaline-2-carbonitrile derivatives. Arzneimittelforschung 55(12), 754-761 (2005).
69. Jaso A, Zarranz B, Aldana I, Monge A. Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents. J. Med. Chem. 48(6), 2019-2025 (2005).
70. Amaia A, Pachon G, Cascante M, Creppy EE, Monge A, Lopez De Cerain A. Selective toxicity of a quinoxaline 1,4-di-N-oxide derivative in human tumour cell lines. Arzneimittelforschung 55(3), 177-182 (2005).
71. Suter W, Rosselet A, Knusel F. Mode of action of quindoxin and substituted quinoxaline-di-N-oxides on Escherichia coli. Antimicrob. Agents Chemother. 13(5), 770-783 (1978).
72. Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 56(1), 53-102 (2004).
73. Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin. Investig. Drugs 18(1), 77-87 (2009).
74. Riley RJ, Hemingway SA, Graham MA, Workman P. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4- benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075). Biochem. Pharmacol. 45(5), 1065-1077 (1993).
75. Delahoussaye YM, Evans JW, Brown JM. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem. Pharmacol. 62(9), 1201-1209 (2001).
76. Cahill A, Jenkins TC, White IN. Metabolism of 3-amino-1,2,4- benzotriazine-1,4-dioxide (SR 4233) by purified DT-diaphorase under aerobic and anaerobic conditions. Biochem. Pharmacol. 45(2), 321-329 (1993).
77. Patterson AV, Robertson N, Houlbrook S et al. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). Int. J. Radiat. Oncol. Biol. Phys. 29(2), 369-372 (1994).
78. Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Strafford IJ. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br. J. Cancer 76(10), 1338-1347 (1997).
79. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br. J. Cancer 72(5), 1144-1150 (1995).
80. Chinje EC, Cowen RL, Feng J et al. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol. Pharmacol. 63(6), 1248-1255 (2003).
81. Prosser GA, Copp JN, Syddall SP et al. Discovery and evaluation of Escherichia coli nitroreductases that activate the anticancer prodrug CB1954. Biochem. Pharmacol. 79(5), 678-687 (2010).
82. Ingraham JL, Maaloe O, Neidhardt FC. Growth of the Bacterial Cell. Sinauer Associates, Inc., Sunderland, MA, USA (1983).
83. Rhee KY, Erdjument-Bromage H, Tempst P, Nathan CF. S-nitroso proteome of Mycobacterium tuberculosis: enzymes of intermediary metabolism and antioxidant defense. Proc. Natl Acad. Sci. USA 102(2), 467-472 (2005).
84. Veine DM, Mulrooney SB, Wang PF, Williams CH Jr. Formation and properties of mixed disulfides between thioredoxin reductase from Escherichia coli and thioredoxin: evidence that cysteine-138 functions to initiate dithiol-disulfide interchange and to accept the reducing equivalent from reduced flavin. Protein Sci. 7(6), 1441-1450 (1998).
85. Frost DJ, Brandt K, Kaufmann T, Goldman R. Interaction of sulfhydryl reactive reagents with components involved in (1,3)-b-glucan synthesis from Candida albicans. Can. J. Microbiol. 41(8), 692-698 (1995).
86. Leitsch D, Kolarich D, Binder M, Stadlmann J, Altmann F, Duchene M. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol. Microbiol. 72(2), 518-536 (2009).
87. Leitsch D, Kolarich D, Wilson I B, Altmann F, Duchene M. Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol. 5(8), e211 (2007).
88. Fu LM, Tai SC. The differential gene expression pattern of Mycobacterium tuberculosis in response to capreomycin and PA-824 versus first-line TB drugs reveals stress- and PE/PPE-related drug targets. Int. J. Microbiol. DOI: 10.1155/2009/879621 (2009) (Epub ahead of print).
89. Heifets L, Simon J, Pham V. Capreomycin is active against non-replicating Mycobacterium tuberculosis. Ann. Clin. Microbiol. Antimicrob. 4, 6 (2005).
90. Capobianco JO, Doran CC, Goldman RC. Mechanism of mupirocin transport into sensitive and resistant bacteria. Antimicrob. Agents Chemother. 33(2), 156-163 (1989).
91. Capobianco JO, Goldman RC. Erythromycin and azithromycin transport into Haemophilus influenzae ATCC 19418 under conditions of depressed proton motive force (dH). Antimicrob. Agents Chemother. 34(9), 1787-1791 (1990).
92. Capobianco JO, Goldman RC. Macrolide transport in Escherichia coli strains having normal and altered OmpC and/or OmpF porins. Int. J. Antimicrob. Agents 4(3), 183-189 (1994).
93. Goldman RC, Scaglione F. The macrolide- bacterium interaction and its biological basis. Curr. Drug Targets Infect. Disord. 4(3), 241-260 (2004).
94. Capobianco JO, Zakula D, Coen ML, Goldman RC. Anti-candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action. Biochem. Biophys. Res. Commun. 190(3), 1037-1044 (1993).
95. Vermeij P, Pennings JL, Maassen SM, Keltjens JT, Vogels GD. Cellular levels of factor 390 and methanogenic enzymes during growth of Methanobacterium thermoautotrophicum dH. J. Bacteriol. 179(21), 6640-6648 (1997).
96. Hasan MR, Rahman M, Jaques S, Purwantini E, Daniels L. Glucose-6- phosphate accumulation in mycobacteria: implications for a novel F420-dependent anti-oxidant defense system. J. Biol. Chem. 285(25): 19135-44 (2010).
97. Purwantini E, Mukhopadhyay B. Conversion of NO2 to NO by reduced coenzyme F420 protects mycobacteria from nitrosative damage. Proc. Natl Acad. Sci. USA 106(15), 6333-6338 (2009).
98. Gustafson DL, Pritsos CA. Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and hypoxic conditions. Cancer Res. 53(22), 5470-5474 (1993).
99. Capobianco JO, Zakula D, Frost DJ et al. Cellular accumulation, localization, and activity of a synthetic cyclopeptamine in fungi. Antimicrob. Agents Chemother. 42(2), 389-393 (1998).
100. Mason RP, Rhodes DG, Herbette LG. Re-evaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J. Med. Chem. 34(3), 869-877 (1991).
101. Leiros HK, Brandsdal BO, McSweeney SM. Biophysical characterization and mutational analysis of the antibiotic resistance protein NimA from Deinococcus radiodurans. Biochim. Biophys. Acta 1804(4), 967-76 (2010).
102. Alauzet C, Mory F, Teyssier C et al. Metronidazole resistance in Prevotella spp. and description of a new nim gene in Prevotella baroniae. Antimicrob. Agents Chemother. 54(1), 60-64 (2010).
103. Soki J, Gal M, Brazier J S et al. Molecular investigation of genetic elements contributing to metronidazole resistance in bacteroides strains. J. Antimicrob. Chemother. 57(2), 212-220 (2006).
104. Schaumann R, Petzold S, Fille M, Rodloff AC. Inducible metronidazole resistance in nim-positive and nim-negative bacteroides fragilis group strains after several passages metronidazole containing columbia agar plates. Infection 33(5-6), 368-372 (2005).
105. Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am. J. Gastroenterol. 98(12 Suppl), S18-S23 (2003).
106. Coban AY, Ekinci B, Birinci A, Durupinar B. The effect of fluoroquinolone, metronidazole and some antifungal on Mycobacterium tuberculosis (H37Rv). Infeksiyon Dergisi (Turkish Journal of Infection) 16(2), 183-186 (2002).
107. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38(9), 2054-2058 (1994).
108. Hoff DR, Caraway ML, Brooks EJ et al. Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52(11), 4137-4140 (2008).
109. Via LE, Lin PL, Ray SM et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits and nonhuman primates. Infect. Immun. 76(6), 2333-2340 (2008).
110. Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43(5), 1285-1288 (1999).
111. Dhillon J, Allen BW, Hu YM, Coates AR, Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis. 2(9), 736-742 (1998).
112. Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J. Infect. Dis. 198(2), 275-283 (2008).
113. Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) www.taacf.org